In 2022, long before these stocks saw an increase in value , Seeking Contributors advised investors to buy AbbVie stock ( NYSE:ABBV ), Vertex Pharma ( NASDAQ:VRTX ), Genmab (GMAB), and a variety of other biotechs. In some cases, this advice was given despite the consensus opinion on Wall Street.
The following is a list of some of Seeking Alpha’s editors’ top biotech articles from contributors in 2022:
Calling Genmab a “Strong Buy”
Seeking Alpha contributor Biologics had differing opinions from analysts who were giving bearish calls on the Danish biotech Genmab (GMAB).
In December 2021, Biologics noted that Genmab (GMAB) was trading at a “significant” discount to projected earnings forecasts and assigned the stock a “Strong Buy rating” just before the year got underway.
Since that time, Genmab (GMAB) has increased by around 6% for 2022 even while the overall biotech industry has decreased by about 27% for the year.
Abbvie Stock Outlook
Neglecting the Humira Patent “Cliff” from AbbVie
Edmund Ingham, a contributor to SA, was one of many SA authors to correctly forecast the bull run of AbbVie (ABBV) in 2022 despite an impending “patent cliff” for its top-selling rheumatoid arthritis medication Humira (adalimumab). The patent on Humira, the most used prescription medication in the world, will expire in 2023.
Ingham assigned the company a “Buy” rating in February...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube